Drug aimed at fixing bone marrow after transplant falls short in early trial
NCT ID NCT03948529
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tested a drug called eltrombopag to help people whose bone marrow doesn't recover well after a stem cell transplant for leukemia. The goal was to raise platelet counts and reduce the need for transfusions. The trial was stopped early after enrolling only 9 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Claude Huriez, CHU
Lille, France
Conditions
Explore the condition pages connected to this study.